


Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (Currently Amended) A compound of formula (I)



or a salt, solvate, or physiologically functional derivative thereof, wherein:


- m is an integer of from 2 to 8;
- n is an integer of from 3 to 11;
- with the proviso that m + n is 5 to 19;
- x is zero and y is an integer of 2 or 3 or
- y is zero and x is an integer of 2 or 3;
- z is zero or an integer of 1 or 2;

R^a and R^b are independently selected from hydrogen and C₁₋₄alkyl;


R¹ and R² are independently selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halo, phenyl, and C₁₋₆haloalkyl;

R³ and R⁴ are independently selected from hydrogen and C₁₋₄alkyl with the proviso that the total number of carbon atoms in R³ and R⁴ is not more than 4;


Ar is a group selected from



(a)




(b)



(c)

and



(d)

wherein R^6 represents hydrogen, halogen, $-(CH_2)_qOR^9$, $-NR^9C(O)R^{10}$, $-NR^9SO_2R^{10}$, $-SO_2NR^9R^{10}$, $-NR^9R^{10}$, $-OC(O)R^{11}$ or $-OC(O)NR^9R^{10}$, and R^5 represents hydrogen, halogen or C_{1-4} alkyl;

or R^6 represents $-NHR^{12}$ and R^5 and $-NHR^{12}$ together form a 5- or 6-membered heterocyclic ring;

R^7 represents hydrogen, halogen, $-OR^9$ or $-NR^9R^{10}$;

R^8 represents hydrogen, halogen, halo C_{1-4} alkyl, $-OR^9$, $-NR^9R^{10}$, $-OC(O)R^{11}$ or $-OC(O)NR^9R^{10}$;

R^9 and R^{10} independently represent hydrogen or C_{1-4} alkyl or R^9 and R^{10} together with the nitrogen atom to which they are attached form a 5-, 6- or 7-membered nitrogen-containing ring,

R^{11} represents an aryl (eg phenyl or naphthyl) group which may be unsubstituted or substituted by one or more substituents selected from halogen, C_{1-4} alkyl, hydroxy, C_{1-4} alkoxy or halo C_{1-4} alkyl; and


q is zero or an integer from 1 to 4.

2. (Original) A compound according to claim 1 wherein R^3 and R^4 are independently selected from hydrogen and methyl.


3. (Previously Presented) A compound according to claim 1 wherein R^1 and R^2 each represent hydrogen.

4. (Previously Presented) A compound according to claim 1 wherein the integer m is 4, 5 or 6 and n is 3, 4, 5 or 6.

5. (Previously Presented) A compound according to claim 1 wherein the group Ar is selected from groups (a) and (b).




(a)




(b)


6. (Previously Presented) A compound according to claim 5 wherein groups (a) and (b) are selected from the group consisting of (i) to (xxi):




(i)




(ii)




(iii)




(iv)




(v)




(vi)




(vii)




(viii)




(ix)




(x)




(xi)




(xii)




(xiii)




(xiv)




(xv)




(xvi)




(xvii)




(xviii)



(xix)




(xx)



(xxi)

7. (Previously Presented) A compound of formula (I) according to claim 6 wherein Ar represents group (i).



(i)

8. (Previously Presented) A compound of formula (I) according to claim 1 wherein z represents 2.

9. (Previously Presented) A compound of formula (I) according to claim 1 which is selected from the group consisting of:

4-[(1*R*)-2-({6-[4-(1,1-Dioxido-2,3-dihydro-1-benzothien-6-yl)butoxy]hexyl)amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;

4-[(1*r*)-2-({6-[4-(1,1-dioxido-3,4-dihydro-2*h*-thiochromen-7-yl)butoxy]hexyl)amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;

salts thereof, solvates thereof and physiologically functional derivatives thereof.

10. (Previously Presented) A method for the prophylaxis or treatment of a clinical condition in a mammal for which a selective β_2 -adrenoreceptor agonist is indicated, which comprises administering a therapeutically effective amount of a compound of formula (I), according to claim 1, or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.


11-12. (Canceled)

13. (Previously Presented) A pharmaceutical formulation comprising a compound of formula (I), according to claim 1, or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.

14. (Canceled)

12

~~15~~. (Previously Presented) A process for the preparation of a compound of formula (I), according to claim 1, or a salt, solvate, or physiologically functional derivative thereof, which comprises:
deprotecting a protected intermediate of formula (II):




or a salt or solvate thereof, wherein R^a , R^b , R^1 , R^2 , R^3 , R^4 , m , n ; x , y and z are as defined for the compound of formula (I) or (Ia), Ar^1 represents an optionally protected form of Ar; and P^1 and P^2 are each independently either hydrogen or a protecting group, such that the compound of formula (II) contains at least one protecting group

wherein said deprotecting step is optionally followed by one or more of the following steps in any order selected from the group consisting of:

- (i) removing any protecting groups;
- (ii) separating an enantiomer from a mixture of enantiomers;
- (iii) converting one compound of formula (I) to a different compound of formula (I); and
- (iv) converting the product to a corresponding salt, solvate, or physiologically functional derivative thereof.


13

~~16~~. (Previously Presented) A process for the preparation of a compound of formula (I), according to claim 1, or a salt, solvate, or physiologically functional derivative thereof, which comprises reacting a compound of formula (IV):



(IV)

wherein Ar^1 represents an optionally protected form of Ar; and P^1 and P^2 each independently represent hydrogen or a protecting group, with a compound of formula (V):



(V)


wherein L is a leaving group, and R^a , R^b , R^1 , R^2 , R^3 , R^4 , n, m, x, y and z are as defined for compounds of formula (I);

wherein said reacting step is optionally followed by one or more of the following steps in any order selected from the group consisting of:


- (i) removing any protecting groups;
- (ii) separating an enantiomer from a mixture of enantiomers;
- (iii) converting one compound of formula (I) to a different compound of formula (I); and
- (iv) converting the product to a corresponding salt, solvate, or physiologically functional derivative thereof.

~~14~~

~~17~~. (Previously Presented) A process for the preparation of a compound of formula (I), according to claim 1, or a salt, solvate, or physiologically functional derivative thereof, which comprises reacting a compound of formula (X):



wherein Ar^1 represents an optionally protected form of Ar; P^1 independently represents hydrogen or a protecting group and L is a leaving group, with an amine of formula (XI):



wherein R^a , R^b , R^1 , R^2 , R^3 , R^4 , m, n, x, y and z are as defined; and P^2 represents hydrogen or a protecting group;

wherein said reacting step is optionally followed by one or more of the following steps in any order selected from the group consisting of:

- (i) removing any protecting groups;
- (ii) separating an enantiomer from a mixture of enantiomers;
- (iii) converting one compound of formula (I) to a different compound of formula (I); and
- (iv) converting the product to a corresponding salt, solvate, or physiologically functional derivative thereof.

¹⁵ 18. (Previously Presented) The method according to claim 10, wherein the mammal is a human.

¹⁶ 19. (Previously Presented) The process according to Claim ¹³ 16, wherein L is a halo or sulfonate leaving group.

¹⁷
~~20~~. (Previously Presented) The process according to Claim ¹⁶~~19~~, wherein
L is selected from the group consisting of an alkylsulfonate, an aryl sulfonate,
and a haloalkylsulfonate.

¹⁸
~~21~~. (Previously Presented) The process according to Claim ¹⁴~~17~~, wherein
L is a halo or sulfonate leaving group.

¹⁹
22. (Previously Presented) The process according to Claim ¹⁸~~21~~, wherein
L is selected from the group consisting of an alkylsulfonate, an aryl sulfonate,
and a haloalkylsulfonate.